You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
花旗:君實生物-B(1877.HK)新冠中和抗體有望在全球範圍內首個提交IND申請;多重利好因素,目標價HK $ 50
格隆匯 05-08 09:47

花旗發佈報告稱,受惠於多重利好因素,包括JS016有望成為首個在全球提交IND的新冠中和抗體, 公司申請於A股上交所科創板上市並爭取納入滬港通,以及特瑞普利單抗用於治療尿路上皮癌患者的上市申請獲國家藥品監督管理局受理,該行維持目標價HK $ 50。

5月4日,君實生物發佈公告,就新冠病毒中和抗體與禮來製藥展開合作。禮來製藥將被授予在大中華區以外地區進行產品臨牀開發、生產和銷售的獨佔許可。君實生物管理層表示,公司計劃於2020年5月底在中美分別遞交IND申請並啟動臨牀研究。

PD1方面,公司憑藉世界一流的研發平台,將管道領域進一步擴展到PCSK9,IL-17A,CDK,PI3K,Trop 2 ADC和IL-21。3月,特瑞普利單抗聯合阿昔替尼用於粘膜黑色素瘤被美國FDA授予孤兒藥稱號。臨港生產基地的產能和銷售團隊都在持續擴張中。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account